Project Description:
A Phase 3 open label study to evaluate the pharmacokinetics, safety, tolerability, and efficacy of Lumicaftor in combination with Ivacaftor in subjects 6 through 11 years of age with cystic fibrosis.
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Professionals and Para-Professionals
Unserved or Under-served Populations:
Racial or Ethnic Minorities, Disadvantaged Circumstances, Limited English, Geographic Areas
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A